These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 27840253)
1. Management of Pelvic Metastases in Patients With Testicular Cancer. Jacob JM; Mehan R; Beck SD; Cary C; Masterson TA; Bihrle R; Foster RS Urology; 2017 Apr; 102():159-163. PubMed ID: 27840253 [TBL] [Abstract][Full Text] [Related]
2. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis]. Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511 [No Abstract] [Full Text] [Related]
3. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements. Rabbani F; Gleave ME; Coppin CM; Murray N; Sullivan LD Cancer; 1996 Aug; 78(3):480-6. PubMed ID: 8697394 [TBL] [Abstract][Full Text] [Related]
4. Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. Alanee SR; Carver BS; Feldman DR; Motzer RJ; Bosl GJ; Sheinfeld J Urology; 2016 Sep; 95():128-31. PubMed ID: 27235751 [TBL] [Abstract][Full Text] [Related]
5. Late pelvic recurrence of nonseminomatous testicular carcinoma after negative retroperitoneal lymph node dissection. Borboroglu PG; Amling CL; Roberts JL Urology; 1999 Nov; 54(5):924. PubMed ID: 10754155 [TBL] [Abstract][Full Text] [Related]
6. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. Nicolai N; Miceli R; Artusi R; Piva L; Pizzocaro G; Salvioni R J Urol; 2004 Jan; 171(1):172-6. PubMed ID: 14665870 [TBL] [Abstract][Full Text] [Related]
10. Risk of Recurrence for Clinical Stage I and II Patients With Teratoma Only at Primary Retroperitoneal Lymph Node Dissection. Liu NW; Cary C; Strine AC; Beck SD; Masterson TA; Bihrle R; Foster RS Urology; 2015 Nov; 86(5):981-4. PubMed ID: 26232690 [TBL] [Abstract][Full Text] [Related]
11. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Steiner H; Leonhartsberger N; Stoehr B; Peschel R; Pichler R Eur Urol; 2013 Jun; 63(6):1013-7. PubMed ID: 23021090 [TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma. Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854 [TBL] [Abstract][Full Text] [Related]
16. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study. Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263 [TBL] [Abstract][Full Text] [Related]
17. Is there still a place for retroperitoneal lymph node dissection in clinical stage 1 nonseminomatous testicular germ-cell tumours? A retrospective clinical study. Dieckmann KP; Anheuser P; Kulejewski M; Gehrckens R; Feyerabend B BMC Urol; 2018 Oct; 18(1):95. PubMed ID: 30367648 [TBL] [Abstract][Full Text] [Related]